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Abstract
External cephalic version (ECV) at term is a safe proce-
dure and reduces the incidence of cesarean sections for
breech presentation. One of the known complications,
however, is an ECV-related disruption of the placental
barrier and a subsequent transfusion of fetal blood into
maternal circulation. While the incidence of ECV-related
fetomaternal hemorrhage (FMH) has been determined
recently in a large trial using a manual Kleihauer-Betke
test (KBT), questions remain on the amount of ECV-relat-
ed FMH. KBT, which detects fetal red blood cells (RBC)
on the basis of acidic resistance of fetal hemoglobin
(HbF), is known to be a sensitive test, yet prone to pro-
cedural errors limiting its accuracy in quantifying FMH. In
this study we investigated 50 patients for FMH before
and after ECV, using a dual-color flow cytometric test kit
with a lower limit of quantification of 0.05% fetal RBC in
maternal peripheral blood. Three patients had a quanti-
fiable increase of fetal RBC detected after ECV (0.06%;
0.08%; 0.1%). None of these subtle increments was pre-
dictable by ECV-related clinical parameters or translated
into fetal compromise. Using a sensitive and accurate
flow cytometric test method, our data provide further
assurance to mothers on the safety of ECV at term.
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Introduction
Planned cesarean sections have become the standard
mode of delivery for women with breech presentation
at term. To reduce the number of cesarean sections for
this indication, current evidence recommends external
cephalic version (ECV) as a safe procedure, which
improves the chance of cephalic birth given that the
appropriate selection criteria and safety measures are
applied w11x. Although there are solid data on its safety,
specific complications of ECV have been reported w5x.
Most notable among these complications is the disrup-
tion of the placental circulation-barrier, with ensuing feto-
maternal hemorrhage (FMH), commonly defined as a
transfusion of an equivalent of more than 30 mL fetal
blood into the maternal circulation. However, none of the
small studies or case reports addressing this issue had
the necessary statistical power to provide reliable data
on the incidence of FMH. Only recently has a cohort
study encompassing a total of 1311 women been pub-
lished; this work tested the amount of fetal cells in the
maternal circulation before and after ECV using a manual
Kleihauer-Betke test (KBT) w2x. In this well-powered trial,
3% of all patients had a positive KBT after ECV, with one
patient having an equivalent of more than 30 mL fetal
blood detectable in the maternal circulation. While pro-
viding solid data on the incidence of FMH in ECV, the
authors stress that the known limits of the KBT are of
concern w2, 17x. KBT, which differentiates fetal from
maternal red blood cells (RBC) based on the relative
resistance of RBCs containing hemoglobin F (HbF) to
acid elution, is inexpensive, but known to be prone to a
variety of procedural errors, making the quantification of
FMH difficult w8x. Flow cytometric test methods have
been evolving rapidly, and, by adding additional para-
meters to HbF, are able to control for HbF positive mater-
nal RBC (sF-cells) that are present in women with sickle
cell disease and thalassemia and in up to 25% of healthy
women in the second trimester of pregnancy w14, 17x.
Recently, Porra et al. evaluated a dual-color flow cyto-
metric test method that identifies F-cells by additionally
staining carbonic anhydrase (CA) w18x. As an inducible
enzyme in the respiratory chain, CA is only present in
adult RBCs, allowing for the specific quantification of
more than 0.05% fetal RBC in maternal blood when ana-
lyzing 2=106 RBCs. In the current study, we quantified
the number of fetal cells before and after ECV using this
dual-color flow cytometry test kit and correlated the
amount of FMH with ECV-related parameters.
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Figure 1 Clinical and sonographic parameters surveyed before external cephalic version (ECV) and procedure related risk-factors
documented after ECV.
Materials and methods
A total of 50 women were included in this prospective obser-
vational study of all singleton breech pregnancies during the
year 2007 that were subject to ECV in the department of obstet-
rics and gynecology Klinikum – Innenstadt of the Ludwig-Maxi-
milians University in Munich. All women gave their informed
consent, and the institutional Review Board approved the pro-
tocol. All women with breech presentation at term were evalu-
ated with a scoring system before ECV. We integrated data
regarding amniotic fluid index, fetal and placental position,
enlacement of the umbilical cord, estimated fetal weight, parity,
uterine tone and breech mobility (Figure 1). ECV was attempted
among women with a score of )8 points and was performed
according to the current German guideline on delivery in breech
presentation w10x. During an initial 30-min non-stress test, an i.v.
line was inserted and 5 mL of total venous blood were collected
into ethylenediaminetetraacetate (EDTA) anticoagulant. ECVwas
performed by an experienced consultant and attempted nomore
than three times. After a post-ECV CTG of 30 min we collected
five additional mL of peripheral venous blood and labeled them
as ‘‘post ECV’’.
The procedure was documented with special reference to pre-
sumed risk factors for FMH: pressure on placenta, use of
tocolytic agent, failure of ECV, number of attempts, CTG decel-
erations and perceived pain (Figure 1).
Detection and quantification of fetal erythrocytes was per-
formed with the Fetal Cell Count Kit II (IQ-Products, Groningen,
The Netherlands). In brief, RBCs were washed three times in
phosphate-buffered saline (PAA-Laboratories, Pasching, Austria)
for 30 min in a formaldehyde-containing solution, washed once
more, and then permeabilized with sodium dodecyl sulfate
solution for 4 min at room temperature. RBCs were then stained
with a fluorescein isothiocyanate-labeled monoclonal mouse
anti-human fetal hemoglobin (HbF) antibody (recognizing the
HbF alpha-chain) and a phycoerythin-labeled polyclonal rabbit
anti-human CA antibody (recognizing the CA-II isoform). The
additional antibody for CA removed the need to determine HbF
threshold values, as it distinguished between the physiological
maternal F-cells (HbFq/CAq) and the genuine fetal RBCs (HbFq/
CA–). Prior to flow cytometry, optimal detector amplifications and
compensations were determined using unstained or single-
stained controls as well as cord-blood samples. Data acquisition
was performed on a FACSCalibur flow cytometer (Becton-Dick-
inson, Heidelberg, Germany). For quality control, spiking exper-
iments were performed using a mixture of peripheral blood of
nulliparous non-pregnant individuals and cord blood at various
dilutions. Concomitant test controls to validate and monitor the
quality of flow cytometric procedures were performed using
FetalTrol test samples (IQ-Products, Groningen, The Nether-
lands). In concomitant test controls and spiking experiments, we
were able to confirm the level of quantification of 0.05% fetal
RBC when screening 2=106 maternal erythrocytes, as
described by Porra et al. (2007) w18x.
Data were acquired and analyzed using the Statistical Pack-
age for the Social Sciences (SPSS, Munich, Germany) software
version 15.0. Pre-ECV data as well as post-ECV data were
acquired in a dichotomous fashion and statistically analyzed
using the x2-test.
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Figure 2 Dot plot of the percentage of fetal hemoglobin (HbF)
positive/carbonic anhydrase (CA) negative red blood cells (RBC).
Every circle represents one patient and the results of two blood
samples drawn before and after external cephalic version (ECV).
Gray lines indicate "0.05% change, black line "0 change after
ECV.
Results
FMH volumes were evaluated for all 50 women with
breech presentation at term that opted for a trial of ECV,
both before and after the procedure. For technical rea-
sons, clinical pre-ECV data were not available for three
women, all of whom had -0.05% fetal RBC (HbFq/CA–)
before and after ECV. A percentage of fetal RBC of
0.05% defined the lower limit of quantification of our flow
cytometric test method. This was determined in 124
spiking experiments performed by Porra et al. and con-
firmed in our laboratory in five independent experiments
w18x. When screening 2=106 erythrocytes via flow cyto-
metry with this method out of 50 blood samples, 26 had
quantifiable amounts of fetal RBC before ECV, with
0.49% being the maximal percentage.
Whereas all of our blood samples contained equal or
greater amounts of fetal RBC after ECV, as compared to
before the procedure, only three procedure-related
increases were elevated above 0.05% (0.06%; 0.08%;
0.1%) (Figure 2). No procedure-related parameter pre-
dicted this event, and no fetal compromise was noted in
spite of an estimated FMH of 80 mL. In our study pop-
ulation, none of the five predefined procedure-related risk
factors or the eight parameters surveyed before ECV
(Figure 1) turned out to be an independent risk factor for
the small amount of FMH in the three cases with
)0.05% fetal RBC, as calculated by a x2-test.
Discussion
Several methods to quantify FMH are currently available
w15x. KBT is a time-honored method that is still used in
many laboratories, but has been shown to have a con-
siderable intra- and inter-test variability and to lack accu-
racy to quantify FMH, especially at concentrations of
-1% fetal cell in maternal peripheral blood w4, 8, 13x.
Furthermore, KBT is prone to overestimate FMH due to
the persistence of HbF, which is especially prominent in
patients with hemoglobinopathies, but is also present in
up to 25% of all healthy women in the second trimester
of pregnancy w14, 17x. Monoclonal fluorochrome-labeled
antibodies have been implemented, either in fluores-
cence microscopy or in flow cytometry, which has been
shown to be more sensitive compared to KBT w9x. Fluo-
rescence microscopy has been shown to be equally pre-
cise compared to flow cytometry – which remains the
gold standard for quantification of low concentrations of
FMH, but utilizes less expensive equipment w12, 15x.
Other techniques like the gel agglutination test (GAT)
have a role in determining an amount of fetal erythrocytes
in maternal circulation that exceeds the standard dose of
anti-D immune globulin administered in clinical practice
but are less suitable to detect low concentrations of FMH
w6x. In the same context, dual-color flow cytometry using
anti-HbF and anti-D monoclonal antibodies has been
recently evaluated to simultaneously D-type and assess
optimal doses of anti-D immunoglobulin in a single assay
w19x. In our experiment, we chose a test kit that uses anti-
HbF and anti-carbonic anhydrase Typ II (CA) antibodies
within an established and tested dual-color flow cyto-
metric approach to estimate as precisely and sensitively
as possible the low concentrations of fetal erythrocytes
expected in our study population w18x. Staining HbF, as
in our test method, instead of the D-antigen for discrim-
inating fetal erythrocytes, offers the advantage of being
applicable regardless of the blood group of the mother
or the fetus. A subpopulation of adult erythrocytes, how-
ever, contains HbF. These so-called F-cells are usually
discriminated by their slightly lower expression of HbF
compared to fetal erythrocytes. This somewhat arbitrary
cut-off level can be difficult to define, especially in cases
with large amounts of F cells w7x. To add specificity and
to circumvent the need for an arbitrary cut-off point, a
second monoclonal antibody was added to the test kit
used in our study, staining for CA, which is part of the
respiratory chain and is fully expressed only after birth
w1, 3x. In their study of 124 spiking experiments, Porra et
al. were able to confirm a lower level of quantification of
0.05%, which we were able to reproduce in concomitant
controls. With this test kit the percentage of women with
)0.05% fetal RBC even before ECV was higher than
previously reported w18x. Given that we confirmed our
level of quantification at 0.05% in preliminary experi-
ments as well as in concomitant controls, it is highly
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unlikely that any subtle alterations made by the manu-
facturer to improve the test kit might account for this dif-
ference. Since all of our controls confirmed that the test
method yielded accurate results, we must assume that
our study population happened to have physiologically
elevated levels of fetal RBC. There is some scientific
debate on how to estimate transfused fetal blood volume
from the percentage of fetal RBC in maternal circulation,
and where to draw the line between physiological values
and clinically relevant FMH w16x. For flow cytometric
analysis, 0.85% fetal RBC is considered to be equivalent
to 30 mL fetal whole blood, which is the volume com-
monly used to define clinically relevant FMH w16x. All of
the blood samples tested in this study were substantially
below this threshold before and after ECV. These data,
generated by screening 2=106 erythrocytes via flow
cytometry, were in line with the findings of Boucher et
al., who found a single FMH after ECV among 1311
women screened by single-slide manual KBT with
400=magnification w2x. Boucher et al. reported a total of
40 out of 1311 women as having an increase in RBC
volume after ECV. Given the large study population, their
data are likely to represent the true incidence of FMH
after ECV. Our cytometry data provide further assurance
about the safety of ECV, given that quantifiable percent-
ages of fetal RBCs were only found in three of 50 women,
even in a population with rather high physiologic levels
of fetal RBC before ECV and with a highly precise test
method. Blood samples of these three women barely
crossed the lower limits of quantification.
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